Nom anglais: Jumonji Domain-Containing Histone Demethylases
Descriptor UI:D056484
Tree Number:D08.811.682.690.416.388
Termes MeSH sélectionnés :
Embryonic Development
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Jumonji Domain-Containing Histone Demethylases : Questions médicales les plus fréquentes",
"headline": "Jumonji Domain-Containing Histone Demethylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Jumonji Domain-Containing Histone Demethylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-10",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Jumonji Domain-Containing Histone Demethylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Dioxygenases",
"url": "https://questionsmedicales.fr/mesh/D049308",
"about": {
"@type": "MedicalCondition",
"name": "Dioxygenases",
"code": {
"@type": "MedicalCode",
"code": "D049308",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Jumonji Domain-Containing Histone Demethylases",
"alternateName": "Jumonji Domain-Containing Histone Demethylases",
"code": {
"@type": "MedicalCode",
"code": "D056484",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Danica Galonić Fujimori",
"url": "https://questionsmedicales.fr/author/Danica%20Galoni%C4%87%20Fujimori",
"affiliation": {
"@type": "Organization",
"name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco; San Francisco, CA 94158, USA; Department of Pharmaceutical Chemistry, University of California San Francisco; San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco; San Francisco, CA 94158, USA. Electronic address: danica.fujimori@ucsf.edu."
}
},
{
"@type": "Person",
"name": "James E Longbotham",
"url": "https://questionsmedicales.fr/author/James%20E%20Longbotham",
"affiliation": {
"@type": "Organization",
"name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco, 600 16th Street, Genentech Hall, San Francisco, California 94158, United States."
}
},
{
"@type": "Person",
"name": "Feng Li",
"url": "https://questionsmedicales.fr/author/Feng%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, Shenyang, China."
}
},
{
"@type": "Person",
"name": "Christopher J Schofield",
"url": "https://questionsmedicales.fr/author/Christopher%20J%20Schofield",
"affiliation": {
"@type": "Organization",
"name": "Chemistry Research Laboratory , University of Oxford , 12 Mansfield Road , Oxford OX1 3TA , United Kingdom."
}
},
{
"@type": "Person",
"name": "Anthony Tumber",
"url": "https://questionsmedicales.fr/author/Anthony%20Tumber",
"affiliation": {
"@type": "Organization",
"name": "Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road OX1 3TA Oxford UK christopher.schofield@chem.ox.ac.uk lennart.brewitz@chem.ox.ac.uk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A preliminary cumulative risk assessment of Diethylhexyl phthalate and Dibutyl phthalate based on the inhibition of embryonic development via the PPARγ pathway.",
"datePublished": "2022-07-25",
"url": "https://questionsmedicales.fr/article/35901955",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tiv.2022.105430"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lipid droplets proteome reveals dynamic changes of lipid droplets protein during embryonic development of Carya cathayensis nuts.",
"datePublished": "2023-06-01",
"url": "https://questionsmedicales.fr/article/37268111",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.plantsci.2023.111753"
}
},
{
"@type": "ScholarlyArticle",
"name": "High expression of CFTR in cumulus cells from mature oocytes is associated with high-quality of oocyte and subsequent embryonic development.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36044164",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10815-022-02599-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of IVF culture medium on post-implantation embryonic growth and development with emphasis on sex specificity: the Rotterdam Periconceptional Cohort.",
"datePublished": "2022-06-14",
"url": "https://questionsmedicales.fr/article/36085269",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.rbmo.2022.06.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of Oocyte Cytoplasmic Central Granulation on Embryonic Development, Blastocyst Formation, and Pregnancy Outcome in Assisted Reproductive Technology and Its Mechanism.",
"datePublished": "2022-05-31",
"url": "https://questionsmedicales.fr/article/36029502",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14715/cmb/2022.68.5.22"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxygénases",
"item": "https://questionsmedicales.fr/mesh/D010105"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dioxygenases",
"item": "https://questionsmedicales.fr/mesh/D049308"
},
{
"@type": "ListItem",
"position": 7,
"name": "Jumonji Domain-Containing Histone Demethylases",
"item": "https://questionsmedicales.fr/mesh/D056484"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Jumonji Domain-Containing Histone Demethylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Jumonji Domain-Containing Histone Demethylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Jumonji Domain-Containing Histone Demethylases",
"description": "Comment diagnostiquer une dysfonction des Jumonji ?\nQuels marqueurs biologiques sont associés aux Jumonji ?\nLes biopsies sont-elles utiles pour le diagnostic ?\nQuels tests sanguins sont recommandés ?\nY a-t-il des tests d'imagerie pour ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Embryonic+Development&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels symptômes sont liés aux anomalies des Jumonji ?\nLes troubles neurologiques sont-ils associés ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes varient-ils selon le type de Jumonji ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Embryonic+Development&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Jumonji Domain-Containing Histone Demethylases",
"description": "Peut-on prévenir les dysfonctionnements des Jumonji ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nY a-t-il des vaccins pour prévenir ces dysfonctionnements ?\nL'éducation génétique est-elle importante ?\nLes conseils diététiques peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Embryonic+Development&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?\nLes médicaments peuvent-ils cibler les Jumonji ?\nY a-t-il des traitements naturels recommandés ?\nLes traitements sont-ils personnalisés ?\nLes thérapies combinées sont-elles efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Embryonic+Development&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?\nLes complications sont-elles graves ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles réversibles ?\nLes complications varient-elles selon le type de Jumonji ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Embryonic+Development&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?\nL'âge est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un facteur ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Embryonic+Development&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des Jumonji ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux Jumonji ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de méthylation des histones et l'expression des gènes sont des marqueurs clés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles utiles pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies peuvent aider à évaluer l'expression des Jumonji dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont recommandés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour mesurer les niveaux de protéines associées aux Jumonji peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests d'imagerie pour ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de diagnostiquer directement les Jumonji."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des Jumonji ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de croissance, des anomalies développementales et des cancers peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils associés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements neurologiques peuvent être liés à des mutations des Jumonji."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies cutanées peuvent être observées, notamment dans des syndromes spécifiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de Jumonji ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types de Jumonji peuvent entraîner des symptômes variés selon leur fonction."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la gravité et de la nature de la dysfonction des Jumonji."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des Jumonji ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les individus à risque de dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ces dysfonctionnements ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des Jumonji."
}
},
{
"@type": "Question",
"name": "L'éducation génétique est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques génétiques peut aider à la prévention et à la détection précoce."
}
},
{
"@type": "Question",
"name": "Les conseils diététiques peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais ne prévient pas directement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des inhibiteurs spécifiques sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils cibler les Jumonji ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments expérimentaux ciblent les Jumonji pour traiter des cancers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels recommandés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches nutritionnelles et phytothérapeutiques sont explorées, mais peu prouvées."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des Jumonji."
}
},
{
"@type": "Question",
"name": "Les thérapies combinées sont-elles efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que les thérapies combinées peuvent améliorer les résultats cliniques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers, des troubles métaboliques et des anomalies développementales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être potentiellement mortelles si non traitées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications chroniques peuvent se développer, affectant la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de Jumonji ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier en fonction du type de Jumonji impliqué."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, environnementaux et liés au mode de vie peuvent influencer le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains dysfonctionnements des Jumonji sont plus fréquents avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines est-elle un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut augmenter le risque de dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut accroître le risque de dysfonctionnements des Jumonji."
}
}
]
}
]
}
Diethylhexyl phthalate (DEHP) and dibutyl phthalate (DBP) are the two most widely used plasticizers (PAEs) that may act as endocrine disruptors and cause developmental toxicity....
We measured intrauterine exposure to DEHP and DBP which are the two most widely used phthalates (PAEs) in the cord blood of 50 postpartum women using ultra-HPLC-tandem mass spectrometry and solid-phas...
The mean concentrations of DEHP and DBP were 99.9 μg/L and 24.7 μg/L, respectively. DEHP and DBP were weakly embryotoxic, and the benchmark dose lower confidence intervals were 29.99 and 0.99 μg/mL, r...
The findings suggest that the cumulative risk in pregnant women with a high level of exposure should receive more attention in the future....
Lipid droplets (LD) is an important intracellular organelle for triacylglycerols (TAGs) storage. A variety of proteins on the surface of LD coordinately control the contents, size, stability and bioge...
The purpose of this study was to explore the association of expression of cystic fibrosis transmembrane conductance regulator (CFTR) in cumulus cells (CCs) from mature oocytes with oocyte quality and ...
A total of 338 infertile women who underwent ovarian stimulation cycle of oocyte retrieval in Zhejiang University School of Medicine were retrospectively enrolled in this study. The relative mRNA expr...
The mRNA expression levels of CFTR in CCs were significantly increased in metaphase II (MII) oocytes compared to that in metaphase I (MI) or germinal vesicle (GV) oocytes. The ROC curve analysis illus...
This study suggests that CFTR expression in CCs is associated with the developmental potential of human oocytes....
Are there (sex-specific) differences in first-trimester embryonic growth and morphological development between two culture media used for IVF and intracytoplasmic sperm injection (ICSI) treatment?...
A total of 835 singleton pregnancies from a prospective hospital-based cohort study were included, of which 153 conceived after IVF/ICSI treatment with Vitrolife G-1™ PLUS culture medium, 252 after cu...
Embryos cultured in SAGE 1-Step grew faster than those cultured in Vitrolife G-1 PLUS (beta...
This study shows that SAGE 1-Step culture medium accelerates embryonic growth trajectories compared with Vitrolife G-1 PLUS and naturally conceived pregnancies, especially in male embryos. Further res...
Obesity adversely influences the quality of oocytes and embryos and can affect DNA repair in embryos, leading to reproductive issues. However, the effects of body mass index (BMI) on DNA repair abilit...
A total of 1,141 patients who received the first fresh ICSI cycle treatments were recruited from July 2017 to July 2021. Based on the BMI of the women, all patients were divided into normal weight (18...
In the normal-weight women group, the embryonic development and reproductive outcomes of ICSI cycles were not statistically different between the two subgroups (DFI<30% and DFI≥30%). However, in the o...
When injected sperm with high DFI into the oocytes of overweight/obese women, resulting in lower fertilization, cleavage, and high-quality embryo rates in ICSI cycles, and the decreased early developm...
Embryonic genetic programs are reactivated in response to various types of tissue damage, providing cell plasticity for tissue regeneration or disease progression. In acute conditions, these programs ...
Growth hormone (GH) has been proposed as an adjunct in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles, especially in women with poor ovarian response. However, it is uncle...
This is a retrospective cohort study from a public fertility center in China, in which we performed propensity score-matching (PSM) for female age and AFC in a ratio of 1:1. We compared the cumulative...
After PSM, multivariate analyses showed the cumulative live birth rate to be significantly higher in the GH group than the control group [N = 694, 34.7% vs. N = 694, 27.5%, risk ratio (RR): 1.4 (95%CI...
Women with poor embryonic quality in the previous IVF/ICSI cycles have higher rates of cumulative live birth with GH supplementation....
Members of the sulfotransferase superfamily (SULT) influence the activity of a wide range of hormones, neurotransmitters, metabolites and xenobiotics. However, their roles in developmental processes a...
Since Six1 is required for patterning the embryonic ectoderm into its neural plate, neural crest, preplacodal and epidermal domains, we used loss- and gain-of function assays to characterize the role ...
Our analyses indicates that XB5850668.L is a member of the SULT2 family that plays important roles in patterning the embryonic ectoderm. Some aspects of its influence likely depend on sulfotransferase...
To determine if there is a relationship between paternal factors and embryonic aneuploidy of paternal origin using preimplantation genetic testing for aneuploidy (PGT-A)....
Retrospective cohort....
Academic....
Couples undergoing in vitro fertilization with PGT-A....
None....
To determine if there is an association between paternal age, body mass index (BMI), or semen analysis parameters and paternal aneuploidy....
From January 2015-2020, 453 in vitro fertilization cycles (1,720 embryos) underwent PGT-A using single nucleotide polymorphism microarrays with parental support bioinformatics. The mean (±SD) was 36.5...
No association was found between paternal age, BMI, or semen analysis parameters and paternal aneuploidy....